Evaluating the nature and prevalence of glucocorticoid-induced Type 2 diabetes mellitus in patients with autoimmune bullous diseases (AIBDs).
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llac137
Abstract: Glucocorticoid use in patients with autoimmune bullous disease is associated with significant morbidity, and in some cases, excess mortality. The hyperglycaemic complications arising from glucocorticoid use have been well-documented and range from mild hyperglycaemia to… read more here.
Keywords: evaluating nature; glucocorticoid; autoimmune bullous; type diabetes ... See more keywords